Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Monte Rosa Therapeutics Inc (GLUE)

Monte Rosa Therapeutics Inc (GLUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 205,079
  • Shares Outstanding, K 50,512
  • Annual Sales, $ 0 K
  • Annual Income, $ -135,350 K
  • 60-Month Beta 1.38
  • Price/Sales 206.43
  • Price/Cash Flow N/A
  • Price/Book 1.31
Trade GLUE with:

Options Overview Details

View History
  • Implied Volatility 148.49% ( +88.88%)
  • Historical Volatility 77.29%
  • IV Percentile 40%
  • IV Rank 28.70%
  • IV High 478.48% on 01/19/24
  • IV Low 15.65% on 05/14/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 54
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 1,856
  • Open Int (30-Day) 1,734

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.50
  • Number of Estimates 4
  • High Estimate -0.37
  • Low Estimate -0.59
  • Prior Year -0.71
  • Growth Rate Est. (year over year) +29.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.21 +34.58%
on 06/28/24
4.45 -2.92%
on 07/12/24
+0.16 (+3.85%)
since 06/12/24
3-Month
3.21 +34.58%
on 06/28/24
7.18 -39.83%
on 04/15/24
-2.89 (-40.08%)
since 04/12/24
52-Week
2.44 +77.05%
on 10/27/23
8.84 -51.13%
on 03/26/24
-2.90 (-40.17%)
since 07/12/23

Most Recent Stories

More News
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street

Analysts have high hopes for these three innovation companies in 2024.

BEAM : 26.88 (+3.86%)
EWTX : 22.42 (+0.40%)
GLUE : 4.32 (+6.40%)
Pre-Market Brief: Stocks Climb As Investors Await FOMC Minutes

March S&P 500 futures (ESH23) are trending up +1.12% this morning after three major U.S. benchmark indices closed lower on 2022’s last trading day as market participants braced for the new year with...

ESH23 : 3,957.05s (-0.09%)
LI : 21.28 (-0.75%)
NIO : 4.87 (+4.06%)
TSLA : 248.23 (+2.99%)
FMS : 19.91 (+0.35%)
GLUE : 4.32 (+6.40%)
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates

– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors...

GLUE : 4.32 (+6.40%)
Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

– Presented Preclinical Data at AACR Annual Meeting Supporting Clinical Development of MRT-2359 as Potent and Selective GSPT1-directed Molecular Glue...

GLUE : 4.32 (+6.40%)
Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022

– Data Highlight Essential Role of GSPT1 in Sustaining Myc-induced Translational Addiction in Solid Tumors – BOSTON, April 08, 2022 (GLOBE NEWSWIRE) --...

GLUE : 4.32 (+6.40%)
Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

– Company on Track for Mid-year Filing of Investigational New Drug (IND) Application for Lead Candidate MRT-2359 – – Progressed NEK7 and CDK2 Molecular...

GLUE : 4.32 (+6.40%)
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences

BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader...

GLUE : 4.32 (+6.40%)
Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders

BOSTON and REHOVOT, Israel, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel...

GLUE : 4.32 (+6.40%)
Monte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader...

GLUE : 4.32 (+6.40%)
Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer

BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader...

GLUE : 4.32 (+6.40%)

Business Summary

Monte Rosa Therapeutics Inc. is a biotechnology company. It involved in developing a portfolio of novel small molecule precision medicines which employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 4.84
2nd Resistance Point 4.65
1st Resistance Point 4.48
Last Price 4.32
1st Support Level 4.12
2nd Support Level 3.93
3rd Support Level 3.76

See More

52-Week High 8.84
Fibonacci 61.8% 6.40
Fibonacci 50% 5.64
Fibonacci 38.2% 4.88
Last Price 4.32
52-Week Low 2.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar